Kevin Kalinsky, MD, MS, on Next Steps Following the Phase 3 RxPONDER Trial

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

Following results that were reported at the 2020 San Antonio Breast Cancer Symposium, investigators of the phase 3 RxPONDER trial (NCT01272037) hope to further evaluate the clinical benefit from the addition of chemotherapy to endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer and an Oncotype DX Recurrence Score between 0 and 25.

Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine as well as director of both the Glenn Family Breast Center and of breast medical oncology at Winship Cancer Institute of Emory University, spoke with CancerNetwork® about next steps following the phase 3 RxPONDER trial.


I have a lot of work to do. We were only reporting at about 50% of the events, so we’re still awaiting additional events. And we’ll put this out as data come. We’ll also be reporting things like quality-of-life outcomes and other end points. And then there’s also a translational medicine component to this where we’ve collected primary tissue and lymph nodes involved that weren’t involved, in the hopes that we could also look at additional predictors or prognostic signatures that can help inform this patient population and potentially future studies as well.